GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity ...

Cipla is preparing to enter the weight-loss drug making sector, heating the competition with US-based Eli Lilly & Co and ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

The pharma major is also strengthening its presence in the central nervous system (CNS) therapeutic area, Vohra stated ...

Mumbai: Mumbai-based pharma giant Cipla is gearing up to make an entry into India's rapidly growing weight management market, ...

Key Points Analyst expectations are far above the prices you'd need to pay now to own a couple of biotechnology stocks.Compass Pathways is developing psilocybin as a treatment for depression.Viking ...

A phenotype-based profiling test can help predict whether a patient might respond better to one antiobesity medicine or ...

Cipla Limited is planning to enter the weight management segment in India, announced the company’s MD and global CEO Umang ...

After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead. Shares of Viking ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

Eli Lilly is advancing its Phase 2 clinical trial to test LY3841136 for weight management in obese and overweight adults.